Lunai Bioworks Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Public

  • Employees
  • 12

Employees

  • Stock Symbol
  • 2Q5

Stock Symbol

  • Investments
  • 5

  • Share Price
  • $9.72
  • (As of Friday Closing)

Lunai Bioworks General Information

Description

Lunai Bioworks Inc is an AI-driven biotechnology company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or lifelong cancer remission in some of the deadliest cancers. The Group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. Its reportable segments are BioSymetrics, which derives the maximum revenue, and RENB. Geographically, the Group operates in the United States and Canada.

Contact Information

Formerly Known As
Enochian, Enochian Biopharma, Enochian BioSciences Biopharmaceutical Company, Enochian BioSciences, Putnam Hills, Renovaro Biosciences, Renovaro
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Century City Medical Plaza, 2080 Century City East
  • Suite 906
  • Los Angeles, CA 90067
  • United States
+1 (305)
Primary Industry
Discovery Tools (Healthcare)
Stock Exchange
STU
Vertical(s)
Corporate Office
  • Century City Medical Plaza, 2080 Century City East
  • Suite 906
  • Los Angeles, CA 90067
  • United States
+1 (305)

Lunai Bioworks Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lunai Bioworks Stock Performance

As of 22-May-2026, Lunai Bioworks’s stock price is $9.72.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$9.72 $9.82 $9.41 - $30.58 4.53M -$61.39

Lunai Bioworks Financials Summary

As of 30-Jun-2026, Lunai Bioworks has a trailing 12-month revenue of $52K.

In Thousands,
USD
TTM 30-Jun-2026 FY 2026 30-Jun-2026 FY 2025 30-Jun-2025 FY 2024 30-Jun-2024
EV 55,573 277,561
Revenue 52 52 0 0
EBITDA (3,254) (3,254) (177,269) (85,869)
Net Income (3,562) (3,562) (178,007) (88,426)
Total Assets 9,942 9,942 8,231 163,129
Total Debt 1,338 1,338 10,173 3,787
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Lunai Bioworks Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Lunai Bioworks‘s full profile, request access.

Request a free trial

Lunai Bioworks Patents

Lunai Bioworks Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020294700-A1 Allogeneic t-cell-based hiv vaccine to induce cellular and humoral immunity Inactive 17-Jun-2019
WO-2020257309-A1 Allogeneic t-cell-based hiv vaccine to induce cellular and humoral immunity Inactive 17-Jun-2019
AU-2019306504-A1 Methods and compositions using recombinant dendritic cells for cancer therapy Inactive 15-Jul-2018
WO-2020018413-A1 Methods and compositions using recombinant dendritic cells for cancer therapy Inactive 15-Jul-2018 A61P35/00

Lunai Bioworks Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lunai Bioworks Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Lunai Bioworks‘s full profile, request access.

Request a free trial

Lunai Bioworks Acquisitions (5)

Lunai Bioworks’s most recent deal was a Merger/Acquisition with Neurobridge IP Holdings for . The deal was made on 01-May-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Neurobridge IP Holdings 01-May-2026 Merger/Acquisition Other Commercial Products
BioSymetrics 08-Apr-2025 Merger/Acquisition Decision/Risk Analysis
Renovaro Cube 13-Feb-2024 Merger/Acquisition Discovery Tools (Healthcare)
Cyclomics 01-Feb-2024 Merger/Acquisition Biotechnology
DanDrit 16-Feb-2018 Merger/Acquisition Drug Discovery
To view Lunai Bioworks’s complete acquisitions history, request access »

Lunai Bioworks ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

37.83 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Lunai Bioworks’s complete esg history, request access »

Lunai Bioworks Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Cyclomics Amsterdam, Netherlands 2017
BioSymetrics New York, NY 2017

Lunai Bioworks FAQs

  • When was Lunai Bioworks founded?

    Lunai Bioworks was founded in 2011.

  • Where is Lunai Bioworks headquartered?

    Lunai Bioworks is headquartered in Los Angeles, CA.

  • What is the size of Lunai Bioworks?

    Lunai Bioworks has 12 total employees.

  • What industry is Lunai Bioworks in?

    Lunai Bioworks’s primary industry is Discovery Tools (Healthcare).

  • Is Lunai Bioworks a private or public company?

    Lunai Bioworks is a Public company.

  • What is Lunai Bioworks’s stock symbol?

    The ticker symbol for Lunai Bioworks is 2Q5.

  • What is the current stock price of Lunai Bioworks?

    As of 22-May-2026 the stock price of Lunai Bioworks is $9.72.

  • What is Lunai Bioworks’s current revenue?

    The trailing twelve month revenue for Lunai Bioworks is $52K.

  • What is Lunai Bioworks’s annual earnings per share (EPS)?

    Lunai Bioworks’s EPS for 12 months was -$61.39.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process